Showing : 37–45 of 93
Dr. Christopher Cannon discusses a new kind of cholesterol lowering drug.
HCRI's Executive Director, Cardiometabolic Trials, Christopher Cannon presents the need for triple therapy in patients with AFib and PCI or ACS at ACC 2015.
Dr. Robert Yeh presents on the Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients with and without Myocardial Infarction at ACC 2015.
Dr. Robert Yeh discusses the DAPT Trial results in patients presenting with versus without acute coronary syndromes at ACC 2015
We cordially invite you to join us for one on one discussion regarding the trial and an opportunity to have any of your questions addressed directly by study leadership at one of the following times: HARVARD CLINICAL RESEARCH INSTITUTE EXHIBIT BOOTH: #1212
Controversies in Antithrombotic Strategies After Stenting Scientific Sessionat ACC on Monday March 16, 201.
HCRI Faculty Dr. Laura Mauri and Dr. Robert Yeh along with other colleagues will be presenting analyses from the DAPT Study during the ACC 2015 Scientific Sessions. For additional information on presentation dates and times locations please see below:
HCRI will be at ACC in San Diego! Stop by Booth #1212 at the San Diego Convention Center Sat & Sun (3/14 & 3/15) - 9:30 AM - 4;45 PM Mon (3/16) - 9:00 AM - 2:30 PM
DAPT Trial Secondary Analysis highlighting whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES as well as whether the optimal duration of DAPT therapy differs for BMS and DES